康众医疗上半年营收1.45亿元同比增12.41%，归母净利润-73.94万元同比降110.10%，毛利率下降2.09个百分点

Core Viewpoint - 康众医疗 reported a revenue of 145 million yuan for the first half of 2025, showing a year-on-year growth of 12.41%, but the net profit attributable to shareholders was -739,400 yuan, a decline of 110.10% compared to the previous year [1] Financial Performance - The basic earnings per share for the first half of 2025 was -0.01 yuan, with a weighted average return on equity of -0.09% [2] - The current price-to-earnings ratio (TTM) is approximately 192.98 times, the price-to-book ratio (LF) is about 2.96 times, and the price-to-sales ratio (TTM) is around 8.39 times [2] - The gross profit margin for the first half of 2025 was 38.90%, down by 2.09 percentage points year-on-year, while the net profit margin was -0.47%, a decrease of 6.14 percentage points compared to the same period last year [2] - In Q2 2025, the gross profit margin was 40.93%, an increase of 0.31 percentage points year-on-year and a 5.04 percentage points increase quarter-on-quarter; the net profit margin was 3.05%, down by 5.01 percentage points year-on-year but up by 8.72 percentage points from the previous quarter [2] Expense Analysis - Total operating expenses for the first half of 2025 were 49.48 million yuan, an increase of 2.22 million yuan year-on-year; the expense ratio was 34.15%, a decrease of 2.52 percentage points year-on-year [2] - Sales expenses increased by 8.69% year-on-year, management expenses rose by 42.56%, R&D expenses decreased by 26.21%, and financial expenses surged by 107.53% [2] Shareholder Information - As of the end of the first half of 2025, the total number of shareholders was 4,760, an increase of 35 from the end of the previous quarter, representing a growth of 0.74%; the average market value per shareholder rose from 313,300 yuan to 347,100 yuan, an increase of 10.79% [2] Company Overview - 江苏康众数字医疗科技股份有限公司, established on May 23, 2007, and listed on February 1, 2021, specializes in the research, production, sales, and service of digital X-ray flat panel detectors [3] - The main business revenue composition includes static (52.24%), dynamic (44.67%), and other (3.09%) [3] - The company is classified under the pharmaceutical and biological industry, specifically in medical devices, and is involved in concepts such as in vitro diagnostics, micro-cap stocks, and financing [3]